Health state | Full sample (n = 585) | Restricted sample (n = 429) | ||||
---|---|---|---|---|---|---|
Utility value | 95% CI | Utility value | 95% CI | |||
TDT with non-specific iron overload complication | 0.852 | 0.811 | 0.893 | 0.905 | 0.880 | 0.929 |
TDT with cardiac complication | 0.820 | 0.742 | 0.897 | 0.846 | 0.805 | 0.887 |
TDT with diabetes | 0.815 | 0.711 | 0.919 | 0.839 | 0.788 | 0.890 |
TDT with hypothyroid | 0.853 | 0.761 | 0.945 | 0.838 | 0.787 | 0.889 |
TDT with hypogonadism | 0.841 | 0.785 | 0.896 | 0.860 | 0.827 | 0.893 |
TDT with hypoparathyroidism | 0.894 | 0.832 | 0.955 | 0.856 | 0.815 | 0.897 |
TDT with liver iron overload | 0.826 | 0.778 | 0.875 | 0.929 | 0.907 | 0.951 |
TDT with desferrioxamine (DFO) | 0.893 | 0.880 | 0.906 | 0.779 | 0.707 | 0.852 |
TDT with deferasirox (DFX) | 0.915 | 0.856 | 0.974 | 0.854 | 0.837 | 0.870 |
TDT with deferiprone (DFP) | 0.940 | 0.875 | 1.005 | 0.778 | 0.698 | 0.859 |
TDT with DFO + DFP | 0.903 | 0.841 | 0.964 | 0.749 | 0.691 | 0.808 |
TDT with DFO + DFX | 0.862 | 0.229 | 0.953 | 0.758 | 0.662 | 0.854 |
TDT with DFX + DFP | 0.814 | 0.653 | 0.975 | 0.754 | 0.591 | 0.917 |
TDT on subcutaneous (SC) therapy | 0.893 | 0.879 | 0.906 | 0.779 | 0.706 | 0.852 |
TDT on oral (PO) therapy | 0.918 | 0.860 | 0.976 | 0.949 | 0.902 | 0.997 |
TDT on SC + PO therapy | 0.895 | 0.834 | 0.957 | 0.890 | 0.837 | 0.942 |